Current Report Filing (8-k)

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 8-K

_____________________

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): June 9, 2023

_____________________

 

COEPTIS THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware	001-39669	98-1465952
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
105 Bradford Rd, Suite 420 Wexford, Pennsylvania		15090
(Address of principal executive offices)		(Zip Code)

 

724-934-6467

(Registrant’s telephone number, including area code)

 

____________________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		COEP		Nasdaq Global Market
Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $11.50 per whole share		COEPW		Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company     ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

 

 

 

 

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On June 8, 2023, the Company received a letter (the “Nasdaq Approval Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that its application to list its common stock and warrants on The Nasdaq Capital Market has been approved, and that the Company’s securities will be transferred from The Nasdaq Global Market to the Nasdaq Capital Market at the opening of business on Tuesday, June 13, 2023.

 

The Nasdaq Approval Letter also confirms that effective simultaneously with the transfer to The Nasdaq Capital Market the previously announced deficiency (announced in the Company’s Current Report on Form 8-K that was filed with the Securities and Exchange Commission on December 29, 2022) will be deemed closed.

 

Item 8.01

Other Events

 

On June 9, 2023, the Company issued a press release announcing the transfer of the listing of its securities to The Nasdaq Capital Market, effective as of the opening of business on June 13, 2023. A copy of the press release is included with the Current Report on Form 8-K.

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

Description

 

99.1	Press Release, dated June 9, 2023
104	Cover Page Interactive Data File (formatted in iXBRL)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Coeptis Therapeutics Holdings, Inc.
Date: June 9, 2023	By:	/s/ David Mehalick
		David Mehalick Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3